Shares have climbed nearly 14% so far in 2025.
Bernstein lowers rating on Li Auto, says EV maker will see a ‘bumpier road ahead’
The firm downgraded the Chinese electric vehicle stock to market perform from outperform.
Tuesday’s big stock stories: What’s likely to move the market in the next trading session
Stocks ended Monday near the flatline as investors prepared for the Federal Reserve’s Jackson Hole summit. Here’s what’s on CNBC’s radar Tuesday.
Buy Palo Alto if it sees a post-earnings sell-off, according to this chief investment officer
Investors should be ready to buy the stock if it sees some pressure following the results, says Michael Landsberg, CIO of Landsberg Bennett Private Wealth.
These stocks offer rising dividends and the prospect of higher returns, Morgan Stanley says
Companies that step up their dividends could provide investors with some buffer against volatility.
Stanley Druckenmiller ramps up health-care stock exposure, gets back into Microsoft
The legendary investor, who has never had a down year, took a $100 million stake in Microsoft, after exiting the position in the third quarter of 2024.
CVS shares are breaking out to the upside after a 3-year bear market cycle, according to the charts
Chart strategist Katie Stockton breaks down the technical backdrop in CVS.
This has been one of the best earnings seasons on record, per Goldman Sachs
The earnings season is coming to a close, and Goldman Sachs says that companies’ performance this time is one of the best ever.
Best Stocks: Rounding out our biotech exposure with a big winner, one we missed and another we’re still early on
Josh Brown and Sean Russo break down three biotech names in the Best Stocks list.
UBS upgrades CVS to buy rating, sees further recovery ahead
UBS analyst Kevin Caliendo’s revised price target implies 15% upside ahead for shares of the health care benefit and pharmacy chain.